Kamada (NASDAQ:KMDA) Stock Rating Reaffirmed by HC Wainwright

Kamada (NASDAQ:KMDA)‘s stock had its “buy” rating reissued by equities research analysts at HC Wainwright in a research note issued on Thursday, Benzinga reports. They currently have a $11.00 price objective on the biotechnology company’s stock. HC Wainwright’s price target indicates a potential upside of 98.56% from the company’s current price. HC Wainwright also issued estimates for Kamada’s FY2024 earnings at $0.28 EPS, FY2025 earnings at $0.34 EPS and FY2026 earnings at $0.42 EPS.

Other equities research analysts also recently issued research reports about the company. StockNews.com initiated coverage on Kamada in a report on Sunday, July 21st. They issued a “buy” rating for the company. Stifel Nicolaus started coverage on Kamada in a research note on Wednesday, July 3rd. They issued a “buy” rating and a $18.00 price target for the company.

Kamada Stock Performance

KMDA opened at $5.54 on Thursday. The company has a fifty day moving average price of $5.43 and a two-hundred day moving average price of $5.55. The firm has a market capitalization of $318.44 million, a PE ratio of 24.09 and a beta of 1.06. Kamada has a 52 week low of $4.08 and a 52 week high of $6.53.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. EWA LLC acquired a new stake in shares of Kamada during the fourth quarter worth about $68,000. Calton & Associates Inc. acquired a new stake in Kamada during the 4th quarter worth approximately $111,000. Y.D. More Investments Ltd lifted its stake in Kamada by 107.1% in the fourth quarter. Y.D. More Investments Ltd now owns 29,002 shares of the biotechnology company’s stock valued at $177,000 after buying an additional 15,000 shares in the last quarter. Aristides Capital LLC boosted its holdings in shares of Kamada by 41.6% in the fourth quarter. Aristides Capital LLC now owns 56,635 shares of the biotechnology company’s stock valued at $347,000 after buying an additional 16,635 shares during the period. Finally, Vanguard Group Inc. increased its position in shares of Kamada by 8.2% during the first quarter. Vanguard Group Inc. now owns 1,325,026 shares of the biotechnology company’s stock worth $7,433,000 after acquiring an additional 100,800 shares in the last quarter. 20.38% of the stock is owned by institutional investors and hedge funds.

About Kamada

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite.